0001567619-21-004527.txt : 20210219 0001567619-21-004527.hdr.sgml : 20210219 20210219191851 ACCESSION NUMBER: 0001567619-21-004527 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210204 FILED AS OF DATE: 20210219 DATE AS OF CHANGE: 20210219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rhodes Jennifer J CENTRAL INDEX KEY: 0001568249 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39990 FILM NUMBER: 21657801 MAIL ADDRESS: STREET 1: C/O ADAMAS PHARMACEUTICALS INC. STREET 2: 1900 POWELL ST., SUITE 750 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Angion Biomedica Corp. CENTRAL INDEX KEY: 0001601485 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113430072 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 51 CHARLES LINDBERGH BOULEVARD CITY: UNIONDALE STATE: NY ZIP: 11553 BUSINESS PHONE: (415) 655-4899 MAIL ADDRESS: STREET 1: 51 CHARLES LINDBERGH BOULEVARD CITY: UNIONDALE STATE: NY ZIP: 11553 3/A 1 doc1.xml FORM 3/A X0206 3/A 2021-02-04 2021-02-04 0 0001601485 Angion Biomedica Corp. ANGN 0001568249 Rhodes Jennifer J C/O ANGION BIOMEDICA CORP. 51 CHARLES LINDBERGH BLVD. UNIONDALE NY 11553 0 1 0 0 See Remarks Common Stock 35242 D Stock Option (Right to Buy) 9.52 2030-02-13 Common Stock 116687 D Stock Option (Right to Buy) 7.78 2030-06-17 Common Stock 58343 D Reflects a 1-to-1.55583 stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. 25% of the total shares subject to the option shall vest on the first anniversary measured from January 13, 2020 (the "Vesting Commencement Date") and 1/24th of the shares subject to the option will vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from June 18, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary Amendment made to reflect updated Beneficial Ownership after RSU vesting on January 13, 2021 not previously reflected. /s/ Jennifer J. Rhodes 2021-02-19